stockrow
Saturday 7 November 2026
Export LBRX’s income statement to Excel — free account
LB Pharmaceuticals Inc
LBRX Healthcare Biotechnology
- EPS
- +87.4%
- Free cash flow
- −579.0%
Quarter to June 2026, against a year earlier
42.01
3.92
+10.29%
Follow LBRX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
15.08 | 35.68 | 41.44 | 47.60 |
+4 more quarters Free account |
Net Debt/EBITDA |
6.08 | 16.62 | 21.44 | 64.06 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 1.22 | 1.58 | 0.95 | |
Capex/Depreciation |
(13.44) | (0.32) | (0.39) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.26) | (0.83) | (2.26) | (0.58) | |
Cash per Share |
10.88 | 12.95 | 36.70 | 54.16 | |
Shareholders Equity per Share |
11.03 | 13.41 | 37.45 | 53.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.03 | 13.41 | 37.45 | 53.42 | |
Free Cash Flow |
(37.99) | (23.32) | (18.14) | (3.37) | |
Working Capital |
331.74 | 378.17 | 300.99 | 309.75 | |
Capital Expenditures |
(0.36) | (0.03) | (0.04) | 0.00 | |
Net Current Asset Value |
325.96 | 374.29 | 296.81 | 305.88 | |
| Other line items | |||||
Quick Ratio |
13.91 | 33.53 | 39.67 | 47.31 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.25) | (0.82) | (2.25) | (0.58) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.91 | — | — | — | |
Average Assets |
180.85 | 196.74 | 156.47 | 160.37 | |
Average Common Equity |
118.90 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026